BioCardia, Inc. — Form 8-K
Filed October 19, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
BioCardia announced FDA acceptance of its revised De Novo pre-submission package for the Helix transendocardial delivery catheter (submitted September 2026). FDA raised no safety or performance concerns and identified two possible clearance pathways. Substantive FDA review with written feedback and an approval meeting are expected in Q4 2026. The Helix is an enabling delivery platform backed by data from 15 clinical trials involving ~500 patients.
Why this rating
For a $9.7M market-cap company, regulatory clearance pathway is transformational—enables product commercialization, partnership expansion, and revenue generation. Near-term catalyst-driven but not yet approved.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $1.01 ▲ 10.38% | at our read · unknown $0.91 | +10 min · unknown $0.95 ▲ 3.89% | +30 min · unknown $0.97 ▲ 6.02% | +1 hr pending | +4 hrs pending |
The stock had already moved -9.41% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 19, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.